RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

Introduction: EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients with untreated advanced NSCLC and an EGFR-activating...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-02-01
Edice:	JTO Clinical and Research Reports
Témata:	Carcinoma Non–small cell lung EGFR exon 19 deletion variant Ramucirumab VEGFR inhibition Targeted therapy
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2666364323001674
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!